Transactions
22
Insider / Roivant Sciences Ltd.
MANCHESTER KEITH S
Director at Roivant Sciences Ltd.
- Company
- Roivant Sciences Ltd.
- Ticker
- ROIV
- First filing on record
- November 21, 2025
- Latest trade on record
- September 16, 2026
- SEC filings
- EDGAR ↗
MANCHESTER KEITH S, Director at Roivant Sciences Ltd., has disclosed 22 transactions in ROIV since November 21, 2025: 0 purchases (0 open-market buys) and 20 sales, worth about $154.5M at the reported prices. The latest was filed September 18, 2026, 2 days after the trade.
Open-market buys
0
Sales
20
Avg. disclosure lag
1.5d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months MANCHESTER KEITH S made no purchases and 20 sales worth $154M, plus 2 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
MANCHESTER KEITH S has traded 1 stock on record; the largest by dollars is ROIV.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 5 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 20 | 5,858,561 | $154.5M |
| A | Grant or award | 2 | 15,585 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 13 | 0 | 11 · $89.1M |
| 2025 | 9 | 0 | 9 · $65.4M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| ROIV | Other A | September 16, 2026 | September 18, 2026 | 2d | 10,531 | — | — | derivative | Form 4 ↗ | |
| ROIV | Other A | September 16, 2026 | September 18, 2026 | 2d | 5,054 | — | — | Form 4 ↗ | ||
| ROIV | Sell S | June 30, 2026 | June 30, 2026 | 0d | 200,000 | $35 | $7.1M | Form 4 ↗ | ||
| ROIV | Sell S | June 30, 2026 | June 30, 2026 | 0d | 12,380 | $35 | $437K | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | June 29, 2026 | June 30, 2026 | 1d | 600,000 | $35 | $20.8M | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | June 29, 2026 | June 30, 2026 | 1d | 200,000 | $34 | $6.9M | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | June 26, 2026 | June 30, 2026 | 4d | 325,000 | $34 | $11.1M | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | June 26, 2026 | June 30, 2026 | 4d | 300,783 | $34 | $10.2M | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | February 13, 2026 | February 13, 2026 | 0d | 225,000 | $27 | $6.0M | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | February 13, 2026 | February 13, 2026 | 0d | 150,784 | $26 | $4.0M | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | February 12, 2026 | February 13, 2026 | 1d | 275,000 | $27 | $7.4M | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | February 12, 2026 | February 13, 2026 | 1d | 150,000 | $27 | $4.0M | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | February 11, 2026 | February 13, 2026 | 2d | 425,000 | $27 | $11.3M | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | December 17, 2025 | December 18, 2025 | 1d | 189,538 | $23 | $4.4M | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | December 17, 2025 | December 18, 2025 | 1d | 155,076 | $23 | $3.6M | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | December 17, 2025 | December 18, 2025 | 1d | 432,718 | $23 | $10.0M | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | December 16, 2025 | December 18, 2025 | 2d | 642,282 | $23 | $14.8M | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | December 16, 2025 | December 18, 2025 | 2d | 275,000 | $23 | $6.3M | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | November 19, 2025 | November 21, 2025 | 2d | 175,000 | $20 | $3.5M | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | November 19, 2025 | November 21, 2025 | 2d | 125,000 | $20 | $2.5M | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | November 19, 2025 | November 21, 2025 | 2d | 150,000 | $20 | $3.0M | indirectalso in another filing | Form 4 ↗ | |
| ROIV | Sell S | November 19, 2025 | November 21, 2025 | 2d | 850,000 | $20 | $17.2M | indirectalso in another filing | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| September 18, 2026 | Form 4 | 0001140361-26-037158 | 2 | published | EDGAR ↗ |
| June 30, 2026 | Form 4 | 0001193125-26-291172 | 6 | published | EDGAR ↗ |
| February 13, 2026 | Form 4 | 0001193125-26-052130 | 5 | published | EDGAR ↗ |
| December 18, 2025 | Form 4 | 0001193125-25-325355 | 5 | published | EDGAR ↗ |
| November 21, 2025 | Form 4 | 0001193125-25-291734 | 4 | published | EDGAR ↗ |
Other insiders at Roivant Sciences Ltd.
- Venker Eric President & Immunovant CEO 94 rows
- Sukhatme Mayukh President & CIO 49 rows
- Gold Daniel Allen Director 22 rows
- Gline Matthew CEO 20 rows
- Epperly Melissa B, Director 19 rows
- QVT Financial LP Insider 19 rows
- Fitzgerald Meghan Director 18 rows
- Torti Frank President and Vant Chair 17 rows
- Ramaswamy Vivek Insider 15 rows
- Pulik Richard CFO 14 rows
Everyone on file, with contracts and lobbying under the company's name: Roivant Sciences Ltd..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 5 | 22 | November 21, 2025 | September 18, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.